Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25661131 | 1.00 | SUCNR1 (0.44) | SUCNR1LMNATSHRPMP22KDM4E | |
| SCHEMBL25662212 | 1.00 | SUCNR1 (0.44) | SUCNR1LMNATSHRPMP22KDM4E | |
| SCHEMBL25661135 | 1.00 | SUCNR1 (0.44) | SUCNR1LMNATSHRPMP22KDM4E | |
| SCHEMBL25661145 | 0.86 | GABRR1 (0.36) | SUCNR1LMNATSHRPMP22KDM4E | |
| SCHEMBL25661144 | 0.86 | GABRR1 (0.36) | SUCNR1LMNATSHRPMP22KDM4E | |
| SCHEMBL25660882 | 0.84 | — | — | |
| SCHEMBL25660890 | 0.84 | — | — | |
| SCHEMBL17888862 | 0.82 | — | — | |
| SCHEMBL18571110 | 0.78 | — | — | |
| SCHEMBL25660988 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280535-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-09-08 | — | — | US | disclosed |
| US-20210338776-A1 | TREATMENTS AGAINST MOSQUITO-BORNE VIRUSES BASED ON MOSQUITO SALIVARY GLAND PROTEINS | YALE UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-11090313-B2 | Methods for inhibiting muscle atrophy | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10781425-B2 | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2020-09-22 | — | — | US | disclosed |
| US-10697975-B2 | Methods for identifying, diagnosing, and predicting survival of lymphomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200190478-A1 | METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION | CHILDREN'S HOSPITAL MEDICAL CENTER | 2020-06-18 | — | — | US | disclosed |
| US-10668087-B2 | Methods for inhibiting muscle atrophy | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200061083-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190309373-A1 | CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-10-10 | — | — | US | disclosed |
| US-10370715-B2 | Methods for identifying, diagnosing, and predicting survival of lymphomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2005103296-A2 | GLOBAL GENE EXPRESSION ANALYSIS OF HUMAN BRONCHIAL EPITHELIAL CELLS EXPOSED TO CIGARETTE SMOKE, SMOKE CONDENSATES, OR COMPONENTS THEREOF | VECTOR TOBACCO, LTD. (BM) | 2005-11-03 | — | — | WO | disclosed |
| US-20050209181-A1 | Analyzing differential gene expression; mood/behavioral disorders; psychosis; drug screening | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2005-09-22 | — | — | US | disclosed |
| US-20050164231-A1 | Methods for identifying, diagnosing, and predicting survival of lymphomas | NANOSTRING TECHNOLOGIES, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1534305-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | Osteologix A/S (DK) | 2005-06-01 | — | — | EP | disclosed |
| US-20050059147-A1 | Human mesenchymal progenitor cell | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-17 | — | — | US | disclosed |
| WO-2004098619-A2 | TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS | OSTEOLOGIX A/S (DK) | 2004-11-18 | — | — | WO | disclosed |
| EP-1468110-A2 | MOLECULAR SIGNATURES OF COMMONLY FATAL CARCINOMAS | IRM LLC (BM) | 2004-10-20 | — | — | EP | disclosed |
| US-6773883-B2 | DIAGNOSING ENDOMETRIAL CANCER; OBTAIN SAMPLE OF UROGENITAL TISSUE, MONITOR PREFERENTIAL GENE EXPRESSION, PRESENCE OF PREFERENTIAL GENE PRODUCT INDICATES CANCER | THE BRIGHAM & WOMEN'S HOSPITAL, INC. | 2004-08-10 | — | — | US | disclosed |
| WO-2002101357-A9 | MOLECULAR SIGNATURES OF COMMONLY FATAL CARCINOMAS | IRM LLC (BM) | 2004-02-12 | — | — | WO | disclosed |
| WO-2002101357-A2 | MOLECULAR SIGNATURES OF COMMONLY FATAL CARCINOMAS | IRM LLC (BM) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090313-B2 | Methods for inhibiting muscle atrophy | MYOF, PYGM, MTPN | SUCNR1 67/4885LMNA 943/4885TSHR 3311/4885 |
| US-20200061083-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | MYOF, PYGM, MTPN | SUCNR1 67/4885LMNA 943/4885TSHR 3311/4885 |
| US-20220280535-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | MYOF, PYGM, MTPN | SUCNR1 67/4885LMNA 943/4885TSHR 3311/4885 |
| US-10668087-B2 | Methods for inhibiting muscle atrophy | CPT1B, MYOF, TNNC1 | SUCNR1 795/4885LMNA 1626/4885TSHR 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.